Sumitomo Pharma Co., Ltd. (DNPUF) Stock

About Sumitomo Pharma Co., Ltd.

Sumitomo Pharma Co., Ltd. is a global enterprise specializing in the manufacturing and distribution of a diverse portfolio of products, including pharmaceuticals, food ingredients and additives, chemical product materials, and veterinary medicines. Its operations span key international markets, notably Japan, North America, and China. The company's extensive pharmaceutical division develops and markets therapeutic agents for a wide array of medical conditions. These encompass neurological disorders such as Parkinson's disease and epilepsy; mental health challenges including depression and atypical psychosis; cardiovascular issues like hypertension, angina pectoris, and arrhythmia; and metabolic diseases like type 2 diabetes. Additionally, Sumitomo Pharma addresses conditions such as uterine fibroids, systemic fungal infections, pruritus, advanced prostate cancer, overactive bladder, chronic obstructive pulmonary disease (COPD), and Fabry disease. It also provides specialized treatments like cultured thymus tissue for pediatric congenital athymia and carbapenem antibiotics. Beyond its pharmaceutical offerings, Sumitomo Pharma supplies the food industry with various ingredients and additives, such as polysaccharides and different seasonings, including bases for soups and bouillons. Its chemical product materials segment caters to diverse sectors, offering pharmaceutical excipients, components for personal care items, coatings, industrial applications, and electronic materials. Furthermore, the company extends its expertise to the animal health sector, providing veterinary pharmaceuticals for both companion animals (like dogs and cats) and a broad spectrum of livestock, including cattle, swine, poultry, horses, and aquacultured fish. Sumitomo Pharma actively fosters innovation through numerous collaborations and strategic alliances. Its key partners include Healios K.K., Keio University, RIKEN, the Center for iPS Cell Research and Application (CiRA), Kyoto University, and Aikomi Co., Ltd. The company also holds a joint development agreement with SanBio Company Limited, a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd., and a strategic alliance with Roivant Sciences Ltd. Established in 1897, Sumitomo Pharma Co., Ltd. is headquartered in Osaka, Japan. The company transitioned to its current name in April 2022, having previously been known as Sumitomo Dainippon Pharma Co., Ltd. It operates as a subsidiary of Sumitomo Chemical Company, Limited.

Sumitomo Pharma Co., Ltd. is headquartered in JP.

Sumitomo Pharma Co., Ltd. (DNPUF) stock trades at $8.41 with a market capitalization of $3.77B. The stock is valued at a price-to-earnings (P/E) ratio of 4.78, price-to-book of 1.75, price-to-sales of 1.27. Over the past 52 weeks the stock has ranged between $7.24 and $19.20, and currently trades 56.2% below its 52-week high.

On profitability, Sumitomo Pharma Co., Ltd. generates a return on equity (ROE) of 41.78% — well above the market average, a sign of a high-quality business, return on capital employed of 9.44%, an operating margin of 11.11%, a net profit margin of 23.58%.

Official website: www.sumitomo-pharma.com